Literature DB >> 18295216

Uterine artery embolization, hysterectomy, or myomectomy for symptomatic uterine fibroids: a cost-utility analysis.

Joyce H S You1, Daljit Singh Sahota, Pong Mo Yuen.   

Abstract

OBJECTIVE: To compare the cost and quality-adjusted life-years (QALYs) of hysterectomy, myomectomy, and uterine artery embolization (UAE) for symptomatic control of uterine fibroids.
DESIGN: A cost-utility analysis conducted by using Markov modeling.
SETTING: The analysis was conducted from the perspective of Hong Kong society. PATIENT(S): A hypothetical cohort of patients presenting with symptomatic uterine fibroids. INTERVENTION(S): Hysterectomy, myomectomy, or UAE. MAIN OUTCOME MEASURE(S): Health-care resource use and QALYs over 5 years. RESULT(S): The base-case analysis showed that hysterectomy was the most effective treatment (4.368 QALYs), followed by myomectomy (4.273 QALYs) and UAE (4.245 QALYs) over 5 years. Hysterectomy was less costly (USD8418) (1USD = 7.8HKD) than UAE (USD8847) and myomectomy (USD9036). Monte Carlo 10,000 simulations showed that the hysterectomy group was less costly than the UAE and myomectomy groups 84.1% and 79.1% of the time, and it also gained higher number of QALYs than the UAE and myomectomy groups over 97% of the time. CONCLUSION(S): Hysterectomy appears to be more cost-effective than myomectomy and UAE for management of symptomatic uterine fibroids over a 5-year period among patients who do not have a preference for uterus-conserving interventions.

Entities:  

Mesh:

Year:  2008        PMID: 18295216     DOI: 10.1016/j.fertnstert.2007.11.078

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  3 in total

1.  Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT.

Authors:  Jane Daniels; Lee J Middleton; Versha Cheed; William McKinnon; Dikshyanta Rana; Fusun Sirkeci; Isaac Manyonda; Anna-Maria Belli; Mary Ann Lumsden; Jonathan Moss; Olivia Wu; Klim McPherson
Journal:  Health Technol Assess       Date:  2022-04       Impact factor: 4.106

Review 2.  Updated approaches for management of uterine fibroids.

Authors:  Aymara Mas; Marta Tarazona; Joana Dasí Carrasco; Gloria Estaca; Ignacio Cristóbal; Javier Monleón
Journal:  Int J Womens Health       Date:  2017-09-05

3.  Durable Improvement in Generic and Fibroid-Specific Quality of Life in Women Treated with Transcervical Fibroid Ablation with the Sonata System After Three Years.

Authors:  Kelly Roy; James K Robinson
Journal:  J Gynecol Surg       Date:  2022-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.